<DOC>
	<DOCNO>NCT01112202</DOCNO>
	<brief_summary>Dabigatran represent new class promising anticoagulation agent . As oral direct thrombin inhibitor effective prevent venous thromboembolism patient undergo elective orthopaedic surgery . This ex vivo study undertaken investigate ex-vivo effect PradaxaÂ® different coagulation parameter .</brief_summary>
	<brief_title>Effect Dabigatran Coagulation parameters-an ex Vivo Study</brief_title>
	<detailed_description>This mono-centric , open-label study undertaken validate effect Dabigatran coagulation parameter plasma sample 70 patient hip knee replacement surgery treat Dabigatran 150-220 mg/d . Plasma sample obtain blood collection , 2 hour 12-14 hour Dabigatran dose steady state ( 3rd - 5th day ) .</detailed_description>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Age &gt; 18 Hemorrhagic disorder Liver disease Anemia Severe renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>direct thrombin inhibitor</keyword>
	<keyword>Dabigatran</keyword>
	<keyword>Coagulation parameter</keyword>
</DOC>